A panel discussion at AMCP Nexus 2021 explored the current biosimilar landscape and level of uptake, with survey results showing payers are accepting of biosimilars and that a majority support nonmedical switching.
Payers were found to be more accepting of biosimilars than expected, according to survey results presented during a panel discussion at the Academy of Managed Care Pharmacy’s 2021 Nexus meeting.
The panel discussed the current trajectory of biosimilar adoption, barriers to adoption, and how coverage of biosimilar is anticipated to evolve in the coming years.
Tasmina Hydery, PharmD, MBA, BCGP, assistant director of integrated delivery solutions at AmerisourceBergen/Xcenda, talked about the anticipation surrounding the launches of the 6 FDA-approved adalimumab biosimilars, which are scheduled to enter the US market in 2023, and the interchangeable formulation of Semglee (insulin glargine), the first biosimilar to be approved in the United States.
Hydery mentioned that reactions to the potential for interchangeable biosimilars have been positive; however, states have enacted their own laws, which has caused confusion among payers, patients, and providers on whether interchangeability designations will have an impact.
“Some of the FDA leaders have noted that there's potential for cost savings, there's more competition in the marketplace, and now there's potentially more access to affordable products. But there are others that are speculating whether this will actually translate into uptake and how important it is to educate pharmacists about the different state laws and how pharmacies will actually operationalize the availability of the interchangeable biosimilars,” said Hydery.
Another challenge for biosimilar uptake concerns patent thickets, which Congress is working to address, according to Hydery. She said that by limiting the number of continuation and divisional patents that can be filed for a single patent and capping the number of patents that could be asserted against a biosimilar product, Congress could prevent future patent thickets.
Cate Lockhart, MS, PharmD, PhD, executive director of the Biologics and Biosimilars Collective Intelligence Consortium, delved into the existing research on coverage, adoption, and utilization patterns of biosimilars, saying that survey results show that among 17 of the largest commercial health plans in the United States, only 14% cover biosimilars as preferred products.
Lockhart also explained how filgrastim biosimilar Zaxio (filgrastim-sndz) is listed as a preferred product on coverage plans 51% of the time, which is much higher than infliximab-abda and infliximab-dyyb (0% and 5%, respectively). Additionally, she said that although biosimilar uptake has been slow, regression models estimate that the market share of reference products would decline by about 0.38% to 0.46% for each month a biosimilar is available.
However, despite uptake being on the rise, only 35% of payers are continuing cover all biosimilars, according to Jennifer Snow, MPH, vice president of reimbursement policy insights at AmerisourceBergen/Xcenda. Health plans (48%) and pharmacy benefit managers (22%) were most likely to cover all biosimilars whereas 100% of integrated delivery networks surveyed said they only cover some biosimilars.
Overall, Snow said that 59% of payers agreed that biosimilars have provided their organization with meaningful cost savings. Most surveyed payers said that they contract with biosimilar manufacturers for select biosimilars and that they would cover the biosimilar for the same indications as the reference product (75% and 55% respectively), regardless of whether the indications were approved by the FDA.
Snow proclaimed that the statistics that surprised her most were that 96% of the surveyed payers agreed that biosimilars are safe and effective for treatment-naive patients and that 92% agreed that switching to a biosimilar from a reference product was safe and effective. Cost savings were also cited as the most important factor driving the adoption of biosimilars, with 65% of payers ranking it as their top influencing factor, followed by 27% who chose interchangeability status as their top influencing factor.
Lockhart noted Kaiser Permanente’s success in obtaining substantial biosimilar uptake, achieving a 95% utilization rate for filgrastim-sndz and 80% rate for infliximab-dyyb, both much higher than the national average (32% and 3%, respectively). Lockhart said they were able to achieve such numbers by adopting the biosimilars shortly after they received FDA approval.
Finally, Lockhart explained that despite biosimilar adoption having a slow start, the United States is starting to see increased utilization, with less lag times between approval and launch. Additionally, many managed care settings are seeing success by implementing strategies to encourage biosimilar use and are anticipating pharmacy benefit biosimilars and identifying potential formulary strategies.
“There's a lot of hope and there's a lot of people who I think are really invested in doing this, because we want patients to get access to the medications they need at a cost they can afford. And we've seen some successes with that,” said Lockhart.
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More
SDOH in Cancer Care Highlight Multifactorial Equity Issues
December 6th 2023A trio of speakers addressed the importance of social determinants of health (SDOH) in cancer care on day 1 of the 46th annual San Antonio Breast Cancer Symposium in the session, “Social Determinants of Health: Impact on Cancer Care.”
Read More